Inclusion Criteria:

          -  Male or female, at least 18 years of age. For patients aged <20 years and enrolled in
             Japan, a written informed consent should be obtained from the patient and his or her
             legally acceptable representative

          -  Histologically or cytologically documented non-squamous NSCLC with completely
             resectable (Stage II - IIIB N2) disease (according to Version 8 of the IASLC Cancer
             Staging Manual [IASLC Staging Manual in Thoracic Oncology 2016]).

          -  Complete surgical resection of the primary NSCLC must be deemed achievable, as
             assessed by a MDT evaluation (which should include a thoracic surgeon, specialised in
             oncologic procedures).

          -  Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1 at enrolment, with no
             deterioration over the previous 2 weeks prior to baseline or day of first dosing

          -  A tumour which harbours one of the 2 common EGFR mutations known to be associated with
             EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR
             mutations (ie, T790M, G719X, Exon20 insertions, S7681 and L861Q).

        Exclusion Criteria:

          -  Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required
             steroid treatment, or any evidence of clinically active ILD.

          -  History of another primary malignancy, except for the following: Malignancy treated
             with curative intent and with no known active disease ≥2 years before the first dose
             of investigational product (IP) and of low potential risk for recurrence; Adequately
             treated non-melanoma skin cancer or lentigo malignancy without evidence of disease;
             Adequately treated carcinoma in situ without evidence of disease

          -  Patients who have pre-operative radiotherapy treatment as part of their care plan

          -  Mixed small cell and NSCLC histology

          -  Stages I, IIIB N3, IIIC, IVA, and IVB NSCLC

          -  T4 tumours infiltrating the aorta, the oesophagus and/or the heart; and/or any bulky
             N2 disease

          -  Patients who are candidates to undergo only segmentectomies or wedge resections

          -  Prior treatment with any systemic anti-cancer therapy for NSCLC including
             chemotherapy, biologic therapy, immunotherapy, or any investigational drug

          -  Prior treatment with EGFR-TKI therapy

          -  Current use of (or unable to stop use prior to receiving the first dose of study
             treatment) medications or herbal supplements known to be strong inducers of cytochrome
             P450 (CYP) 3A4 (at least 3 weeks prior)